← Back to Search

Behavioral Intervention

iRaPID for HIV Prevention Program (iRaPID Trial)

N/A

Waitlist Available

Research Sponsored by University of Connecticut

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 month

Awards & highlights

iRaPID Trial Summary

This trial is testing a new program that provides people who inject drugs with same-day access to HIV prevention medication (PrEP) and treatment for opioid addiction (OAT).

Eligible Conditions

HIV Prevention Program
Opioid Use Disorder

iRaPID Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 month

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 month

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 month for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Acceptability

Adherence to PrEP

Feasibility - participants randomized

+6 more

iRaPID Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: iRaPIDExperimental Treatment1 Intervention

Participants randomized to the iRaPID program will receive: a) same-day access to PrEP and OAT and educational counseling by the APN; b) safety-check phone calls/SMS; c) follow-up phone call/SMS; and d) clinical visit at Day 30

Group II: Standard of CareActive Control1 Intervention

PWID participants randomized to the training as usual (TAU) will follow the existing clinical guidelines to receive PrEP, OAT, or both.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

iRaPID

2021

N/A

~50

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of ConnecticutLead Sponsor

181 Previous Clinical Trials

157,995 Total Patients Enrolled

3 Trials studying HIV Prevention Program

408 Patients Enrolled for HIV Prevention Program

National Institute on Drug Abuse (NIDA)NIH

2,467 Previous Clinical Trials

2,619,073 Total Patients Enrolled

1 Trials studying HIV Prevention Program

526 Patients Enrolled for HIV Prevention Program

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are any further participants being taken on for this clinical experiment?

"This trial, which was posted on July 26th 2021 and recently updated on September 2nd 2022 is no longer recruiting patients. Nevertheless, clinicaltrials.gov lists an additional 294 studies that are actively looking for participants at this time."

Answered by AI

Recent research and studies

Medical CareJournal

Effectiveness-implementation Hybrid Designs

Curran, Geoffrey M., Mark Bauer, Brian Mittman, Jeffrey M. Pyne, and Cheryl Stetler. 2012. “Effectiveness-implementation Hybrid Designs”. Medical Care. Ovid Technologies (Wolters Kluwer Health). doi:10.1097/mlr.0b013e3182408812.

Implementation ScienceJournal

Fostering Implementation of Health Services Research Findings into Practice: A Consolidated Framework for Advancing Implementation Science

Damschroder, Laura J, David C Aron, Rosalind E Keith, Susan R Kirsh, Jeffery A Alexander, and Julie C Lowery. 2009. “Fostering Implementation of Health Services Research Findings into Practice: A Consolidated Framework for Advancing Implementation Science”. Implementation Science. Springer Science and Business Media LLC. doi:10.1186/1748-5908-4-50.

Implementation ScienceJournal

A Systematic Review of the Use of the Consolidated Framework for Implementation Research

Kirk, M. Alexis, Caitlin Kelley, Nicholas Yankey, Sarah A. Birken, Brenton Abadie, and Laura Damschroder. 2015. “A Systematic Review of the Use of the Consolidated Framework for Implementation Research”. Implementation Science. Springer Science and Business Media LLC. doi:10.1186/s13012-016-0437-z.

clinicaltrials.govStudy